S-14671

S-14671 is a drug that was developed by the pharmaceutical company Servier. It is classified as an antidepressant, specifically a serotonin-norepinephrine reuptake inhibitor (SNRI).

Pharmacology[edit | edit source]

S-14671 works by inhibiting the reuptake of serotonin and norepinephrine, two neurotransmitters in the brain. This increases the amount of these neurotransmitters available in the brain, which can help to alleviate symptoms of depression.

Development and Clinical Trials[edit | edit source]

S-14671 was developed by Servier Laboratories, a French pharmaceutical company. It underwent clinical trials to assess its safety and efficacy as a treatment for depression. However, the results of these trials have not been publicly disclosed, and it is unclear whether the drug is currently being marketed.

Side Effects[edit | edit source]

As with all drugs, S-14671 has the potential to cause side effects. These can vary widely between individuals and may include nausea, headache, insomnia, and dizziness. It is important for patients to discuss any potential side effects with their healthcare provider before starting treatment.

See Also[edit | edit source]

S-14671 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.